Theranica has announced the closing of its Series C funding round, with a first closing of US$45 million. New Rhein Healthcare Investors led the round, with wide participation from existing investors aMoon, Lightspeed Venture Partners, LionBird, Takoa Invest and Corundum Open Innovation.
Due to high investor interest, the company has extended the financing round, planning a final closing in October. Proceeds of the new funds will focus on expanding Theranica’s commercial activity in the USA, according to a press release.
“In spite of several decades of new medications, millions of individuals still suffer from frequent debilitating migraine headaches,” said Alon Ironi, CEO of Theranica. “Over the last couple of years, we have verified the three fundamental conditions of a successful new prescribed therapy in the USA: healthcare providers have confidence in prescribing our Nerivio for treating migraine; patients get significant clinical benefit from using it; and payers realise the importance of providing their insured members with access to this therapy. With this triad demonstrated, we needed the appropriate funding to unleash the huge potential of Nerivio in the USA.”
Nerivio is a US Food and Drug Administration (FDA)-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in people aged 12 and older. Uniquely worn on the upper arm at the onset of a migraine attack, Nerivio alleviates migraine headache and associated symptoms by utilising remote electrical neuromodulation to trigger an endogenous analgesic mechanism, known as conditioned pain modulation.
Greg Parekh, founder and managing partner at New Rhein Healthcare Investors, said: “A sequence of recent discoveries in neuroscience is driving a paradigm shift in the treatment of neurological diseases. We believe Nerivio represents the first major breakthrough for the non-pharmacological treatment of migraine headaches. We spent a year exploring this market and its participants prior to choosing to invest into Theranica, and believe the migraine medical community and patients are at a critical inflection point in their understanding of the benefits of Nerivio. With our pharma backgrounds, we were highly impressed with Theranica’s clinical data and user-friendly product design. We look forward to supporting the company in its commercial expansion.”
The release notes that multiple clinical trials, and several real-world evidence studies with thousands of patients, have shown Nerivio to be comparable to standard-of-care pharmacological options, and able to be used as a standalone treatment or in combination with existing treatments. Eligible for insurance coverage and available to patients seeking cost-effective, drug-free therapies for migraine, Nerivio can be prescribed by any certified healthcare provider in the USA and is shipped to patients’ homes through several specialty pharmacies.
“More than half of the 40 million Americans who live with migraines are unsatisfied with their current treatments,” said Shimon Eckhouse, chairman and co-founder of Theranica. “We are encouraged by the amazing feedback we have received from the tens of thousands of patients already using Nerivio and are determined to make Nerivio a first-line therapy. We are pleased to have New Rhein join Theranica as the lead investor of round C and as a partner that will play a key role in building and maximising the value of the company. Theranica’s excellent clinical data and positive feedback from both patients and providers, combined with our strong financial position, will enable us to bring our solutions to millions of patients in the USA and worldwide.”